Articles On Recce Pharmaceuticals (ASX:RCE)

The ASX200 has run up 1.16 per cent to be trading in record territory at 7,785 points. All sectors, except Healthcare are in the green. Financials lead the gains, up more than 1.6 per cent. Real estate is following closely up about 1.4 p...

Recce Pharmaceuticals (ASX: RCE), who has been pioneering a new class of synthetic anti-infectives, has secured a Trademark Registration for RECCE® by the Canadian Intellectual Property Office. The International Trademark Registration No...

The ASX200 has traded down well over a per cent this morning – performing worse than predicted. All sectors, except Energy and Real Estate, have been in the red, with Materials shedding more than 2 per cent. Utilities is also making smal...

Recce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its RECCE 327 (R237) synthetic antibiotic, which will be used to treat urinary tract infection (UTI) and urosepsis. The four subjects were do...

There was good news for those with property investments today… the median price of a house in Australia has gone up to $933,800 – that’s a rise of $13,400 in just one quarter. Not such good news for those trying to invest in property, as...

Recce Pharmaceuticals (ASX: RCE) (FSE: R9Q) announces the successful dosing of the latest group of human participants with RECCE 327 (R327) Administered intravenously at a rate of 20 minutes and a dosage of 3,000mg RCE last traded at...

The weekend begins after a day of record breaking on the ASX. The ASX200 closed well over a per cent up at 7847 points, after peaking at 7453 points earlier in the session. The All Ordinaries – Australia’s index of the largest 500 compan...

Recce Pharmaceuticals announces the receipt of an AUD$11,178,965 R&D Advance from Endpoints Capital Agreement allows Endpoints, a SEC-registered investment advisor, to capture Recce’s Research and Development (R&D) tax incentive...

Research reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=17DBBDB4-E20C-03AC-A84AF5C456D084E9 -Amaero International ((3DA)) by Re...

ASX closed flat, as Coles-led Staples sector gained Iron ore stocks under pressure as iron ore futures continue to fall Bitcoin now nearly at US$56k   The ASX 200 closed +0.13% higher on Tuesday, as gains in Consumer Staples were offset b...

The ASX200 has been trading fairly flat, having headed down about .2 per cent earlier in the session. The drags have included the Real Estate sector, materials and communications. However, consumer staples has led the day so far, up n...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and dropped into the red. In afternoon trade, the benchmark index is down 0.25% to 7,633.2 points. Four ASX shares that are not letting that hold them back are listed b...

Recce Pharmaceuticals (ASX:RCE) highlights ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at the Murdoch Children’s Research Institute (MCRI), Victoria The collaboration has been crucial in delivering positive...

Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX!   Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h...

Recce Pharmaceuticals’ (ASX:RCE) flagship product is a versatile drug called R327 It can be used as a gel to treat wound infections The company is investigating on patients with Diabetes suffering post-surgery complications Share...

Recce Pharmaceuticals (ASX:RCE) has signed a Memorandum of Understanding with Indonesian organisation PT Etana Biotechnologies to accelerate the development of the Australian company's anti-infective portfolio.

We’re here for day two of the RIU Resurgence conference in Perth, and it’s certainly busy here with investors, brokers and a host of uranium, batteries metals and gold companies too. The ASX200 is trading down more than half a per cent w...

Recce Pharmaceuticals (ASX:RCE) develops anti-infectives for a range of issues and post-surgical complications The company has now won a patent in Canada Its lead drug R327 is both injectable and applicable as a gel Shares last t...

Shortly before Without A Fight crossed the finish line to win the 2023 Melbourne Cup, the Reserve Bank of Australia lifted the cash rate once again – by 25 basis points to 4.35 per cent for November. The decision was in line with expert...

The Reserve Bank of Australia has decided to lift the cash rate again — upping it by 25 basis points to 4.35 per cent for November. It’s the 13th raise in only 16 months and follows the nation’s latest inflation data released just two w...

Recce Pharmaceuticals (ASX:RCE) completes dosing of the first male and female subjects in its UTI/urosepsis clinical trial at the highest concentration of R327 The dosing lasts 15 minutes at 3000mg and was approved by an independent safe...

The ASX200 lifted nearly 0.2 of a per cent by the end of the day’s session, with materials taking a late run to gain .8 of a per cent. Energy also added almost half a per cent.   Cryptocurrency Bitcoin has also jumped almost 10 per cent...

Recce Pharmaceuticals (ASX:RCE) UTI trial using flagship anti-infective R327 has been greenlit to go further The company can now dose patients 3000mg in an IV transfusion of 15 minutes RCE continues to compile safety data around IV...

Recce Pharma moves forward to stronger dose in Phase 1/2 trial EMV is bench testing its 2nd Gen ultra-light weight helmet scanner   Recce Pharma moves forward to higher dosage Synthetic anti-infectives producer, Recce Pharmaceuticals (ASX...

The ASX200 is down nearly 1.2 percent with most sectors in the red. Energy is the only sector making gains, up just over a third of a per cent.   Liontown Resources (ASX:LTR) has taken a dive, now down nearly 30 per cent after raising $3...

Recce Pharmaceuticals (ASX:RCE) winds up the September quarter with $8 million in cash The company has registered a new trademark in Vietnam Recce’s R327 trials continue to support the company’s thesis its flagship anti-infective is...

Sonia Madigan: Recce Pharmaceuticals (ASX:RCE) has raised $11 million to continue developing its late-stage drug candidate, anti-infective, R327. Why did the company raise now? RCE CEO, James Graham, is here to explain. James Graham:...

Recce Pharmaceuticals (ASX:RCE) is fast-tracking the development of its synthetic class of potent anti-infectives, with significant progress being made in FY23 In FY23, the Anti-Infective Research Unit at the Murdoch Children’s Research...

The ASX200 ended the week up just, despite the week’s losses totalling more than one and half per cent. Utilities, energy and materials led the gains, while real estate was today’s worst performer, down almost 1.5 per cent. In the gr...

Whilst the ASX200 has slipped .6 of a per cent, that performance is considerably better than futures suggested.  Real estate and health care are the key drags on the market today, losing almost 1 and a half per cent each, while consumer...

Recce Pharmaceuticals (RCE) completes dosing its male and female subjects in its phase I/II UTI clinical trial with Scientia Research The trial evaluates R327 anti-infective at faster infusion rates of 30 minutes at a dosage of 3000mg, w...

Treatment for infectious diseases continues to pose a significant threat to populations worldwide, with the effectiveness of many anti-infective medications lost to antimicrobial resistance (AMR).  However, in this current era where conc...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=7D2FBF3D-0297-B05B-8F498AF62BD096F8 –AFT Pharmaceuticals ((AFP)) by Edi...

Recce Pharmaceuticals (ASX: RCE), a company developing a new class of synthetic antibiotics, is raising $11 million to boost its research program, bolster manufacturing capabilities and expand further into the US. The Sydney-based company,...

The ASX200 gradually climbed today to gain close to half a per cent. Financials registered the highest gains, up nearly 1.3 per cent With that, the big four banks NAB, CBA, Westpac and ANZ all gained around a per cent. Healthcare, on...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from a trading halt and crashed deep into the red. In afternoon trade, the pharmaceutical company's shares are down 26% to 48 cents. Why is the Recce Pharmaceuticals share p...

Recce Pharmaceuticals (RCE) is raising up to $11 million through a strongly supported placement and entitlement offer The placement comprises the issuance of 18.2 million new shares at 44 cents each Funds will be used toward further t...

ASX 200 closes about 0.3% lower, down well over 2.2% for the week. Materials and Consumer discretionary weigh, Healthcare rises. Small caps led by Oliver’s Real Foods, which has leapt mightily despite having no fresh news.   The Aussie...

The ASX200 has traded down about point four of a per cent this morning.  Sector performances varied, with utilities leading with a gain of .7 per cent, while materials stocks shed just shy of a per cent.  Mining giants BHP, FMG and Ri...

The Australian stock market has dropped more than three-quarters of a per cent in the first hours of trade. Energy has been the only sector in the green after oil-producing nations vowed to continue limiting supply. Energy has been up we...

Cannabis biotech Bod surges after good clinical trial results Imricor granted US$1.15m award in the US Recce issued trademark registration in Vietnam   Bod Science’s CBD-based insomnia drug beats placebo Cannabis focused biotech Bod Scien...

Recce Pharmaceuticals (RCE) secures trademark registration for RECCE in Vietnam It was issued by the Intellectual Property Office of Vietnam Vietnam’s pharmaceutical market is expected to reach A$25.2 billion in value by 2026 Recce...

Recce Pharmaceuticals (RCE) reports its R327 gel product saw one elderly patient avoid amputation of an infected toe The company also cited two other patients with antibiotic-resistant infections who both responded well to the treatment...

Recce Pharmaceuticals (RCE) receives the green light to advance to the next cohort of its anti-infective R327 UTI phase I/II clinical trial The Independent Safety Committee agrees R327 is safe and well-tolerated at IV dosages of 2500mg,...

Recce Pharmaceuticals (RCE) kicks off its phase I/II diabetic foot infection trial The company will apply its flagship R327 anti-infective as a topical treatment RCE is using R327 to treat UTIs, burns patients, and now those with DF...

Recce Pharmaceuticals’ (RCE) phase I/II R327 topical burn wound clinical trial successfully treats bacterial infections in all patients to date Clinicians report a visible reduction in bacterial infections within the first 24 hours of us...

The ASX has seen a slight lift, up almost 0.2 per cent in early afternoon trade. Materials are leading the sectors up around half a per cent, good news for those attending Diggers & Dealers in Kalgoorlie. The sector is followed cl...

Mesoblast Ltd (ASX: MSB) shares are sliding again on Tuesday. Shares in the ASX biotech company are down 3.7% at time of writing to 40 cents a share. That puts Mesoblast shares down a painful 55% since the opening bell rang on 3 January....

Recce Pharma surges 20pc on anecdotal results Emyria launches a ketamine-assisted therapy (KAT) program Race Oncology unveils new corporate strategy   Recce surges on anecdotal results Recce Pharma (ASX:RCE) raced higher by more than 20%...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...